Company Overview of ProFoldRx, Inc.
ProFoldRx, Inc. provides protein therapeutics for bio-pharmaceutical companies, research institutions, and government agencies. It also helps companies to create protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. In addition, the company offers services in the areas of protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression services. ProFoldRx, Inc. was founded in 2003 and is based in Aurora, Colorado.
12635 East Montview Boulevard
Aurora, CO 80045
Founded in 2003
Key Executives for ProFoldRx, Inc.
Chief Executive Officer and President
Vice President of Finance & Accounting
Vice President of Business Strategy & Development and General Manager of European Operations
Chief Intellectual Property Counsel
Vice President of Therapeutic Development
Compensation as of Fiscal Year 2014.
ProFoldRx, Inc. Key Developments
Lonza Group AG and BaroFold, Inc. Announce Technology Evaluation Agreement for PreEMT
Jan 16 13
Lonza Group AG and BaroFold, Inc. (ProFoldRx, Inc.) announced a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold's PreEMT(TM) high pressure refolding technology for use in biological development refolding processes. Lonza's evaluation will focus on refolding difficult to express microbial products expressed as inclusion bodies. The PreEMT(TM) unit will be installed for evaluation at Lonza's microbial development and manufacturing plant in Visp, Switzerland. The agreement includes an option for Lonza to extend the platform evaluation to cGMP production analysis.
ProFoldRx, Inc. and Boehringer Ingelheim Announce Strategic Agreement on PreEMT High Pressure Protein Refolding Technology
Nov 13 12
ProFoldRx, Inc. and Boehringer Ingelheim announced that they have entered into a non-exclusive technology and commercial license option agreement. Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold's Pressure Enabled Manufacturing Technology (PreEMT(TM)) that can also be qualified for GMP use. The technology will be installed at Boehringer Ingelheim's microbial facility in Vienna, Austria and will be available for development of biopharmaceutical production processes.
ProFoldRx, Inc. Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12
ProFoldRx, Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|